BioCentury | Aug 28, 2020
Distillery Therapeutics

CRISPR-based gene editing for Wiskott-Aldrich syndrome

DISEASE CATEGORY: Autoimmune INDICATION: Autoimmune Gene editing of mutated WASp in hematopoietic stem and progenitor cells (HSPCs) could treat Wiskott-Aldrich syndrome. The therapy uses an adeno-associated virus serotype 6 (AAV6) vector to deliver a CRISPR-Cas9...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Targeting the NCK1-WIPF1 interaction for enteropathogenic E. coli infection

...infection, diarrhea and necrosis in the small intestine. TARGET/MARKER/PATHWAY: NCK adaptor protein 1 (NCK1; NCK); WAS/WASL...
BioCentury | Jan 31, 2020
Product Development

CSL is harnessing its supply chain expertise to expand into cell and gene therapy

CSL aims to leverage the logistics expertise it built through its plasma business to expand into cell and gene therapy. The company has a sickle cell disease program in Phase I and is lining up...
BioCentury | Jan 8, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture and mouse studies suggest the MRGPRX2 activator mastoparan could help treat Staphylococcus aureus skin infection. In cell-based gene reporter assays, the wasp venom toxin mastoparan activated MRGPRX2-mediated phosphorylation of PLC1, which...
BioCentury | Dec 19, 2018
Translation in Brief

Taking the sting out of AMPs

Massachusetts Institute of Technology researchers led by Timothy Lu have developed a rational-design method for engineering antimicrobial peptides from toxic molecules such as wasp venom, publishing their third approach to developing AMPs this year and...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Esherichia; Pseudomonas; Staphylococcus Mouse studies identified an analog of the wasp-derived peptide polybia-CP that could help treat E. coli , Pseudomonas and Staphylococcus infections. Chemical synthesis and screening in bacterial colony-based assays of polybia-CP analogs...
BioCentury | Jan 17, 2018
Distillery Therapeutics


INDICATION: Allergy Cell culture studies suggest a CD23-mimicking single-domain antibody against IgE could help treat allergy. The single-domain neutralizing antibody mimics CD23, the low-affinity Fc receptor for IgE, to bind IgE with a K d...
BioCentury | Jun 11, 2015
Translation in Brief

Taming toxins for pain

...three different pathways: ulcer formation results from the toxin's activation of Wiskott-Aldrich syndrome-like ( WASL ; N-WASP...
BioCentury | Mar 28, 2013
Distillery Therapeutics

Indication: Dermatology

...N-WASP could help treat Buruli ulcers. In cultured epithelial cells, wiskostatin inhibited the activation of N-WASP...
...steps could include testing wiskostatin in mouse models for M. ulcerans infection and developing additional N-WASP...
BioCentury | Mar 5, 2012
Clinical News

Pharmalgen regulatory update

The U.K.'s NICE issued final guidance recommending ALK-Abello's Pharmalgen to treat IgE-mediated bee and wasp venom allergy. The product is recommended for those who have had a severe systemic reaction to bee or wasp venom...
Items per page:
1 - 10 of 13